We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lapatinib.
- Authors
Moy, Beverly; Kirkpatrick, Peter; Kar, Santwana; Goss, Paul
- Abstract
Lapatinib is a small-molecule kinase inhibitor that targets the epidermal growth factor receptor and the human epidermal growth factor receptor 2 (HER2). In March 2007, lapatinib distosylate monohydrate (Tykerb; GlaxoSmithKline) was approved by the FDA for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab.
- Publication
Nature Reviews Drug Discovery, 2007, Vol 6, Issue 6, p431
- ISSN
1474-1776
- Publication type
Academic Journal
- DOI
10.1038/nrd2332